# Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL

> **NCT03045328** · PHASE2 · COMPLETED · sponsor: **Steven E. Coutre** · enrollment: 22 (actual)

## Conditions studied

- Recurrent Chronic Lymphocytic Leukemia
- Recurrent Small Lymphocytic Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Refractory Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Ibrutinib
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT03045328
- **Lead sponsor:** Steven E. Coutre
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-26
- **Primary completion:** 2020-05-19
- **Final completion:** 2021-08-05
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2021-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03045328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03045328, "Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03045328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*